In vitro immunodiagnostics and post-acute infection syndrome testing
Strategic Profile
The company has outlined a focused plan centered on advancing ViraxImmune for post-acute infection syndromes (PAIS) and pursuing a U.S. Laboratory Developed Test (LDT) market-entry pathway. Virax achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system (February 2026), supporting regulated IVD development readiness and U.S. clinical validation of ViraxImmune.
Cyborg Score Rationale
Virax operates in a high-growth immunodiagnostics market with differentiated ViraxImmune technology and recent regulatory certifications, but faces significant capital constraints and recent listing compliance challenges. The company reported ~$6.4M cash at March 31, 2026 versus ~$2.6M market cap (April 2026). The company executed a 1-for-25 share consolidation (June 26, 2026) to regain compliance with Nasdaq's minimum bid price rule.
Top Insights
Company reported strong early data for Long COVID test and prepared larger validation study (May 2026).
Achieved ISO 13485 and ISO 9001 certification (February 2026) for quality management systems supporting regulated IVD development.
Company is positioned in emerging post-acute infection syndrome diagnostics market with ViraxClear and ViraxVet product portfolios alongside lead ViraxImmune platform.
Named Competitors
COVID-19 diagnostics portfolio — Rapid and molecular COVID-19 diagnostics
Immunology and viral diagnostics — In vitro diagnostics and immunology testing
Viral and infectious disease diagnostics — Blood and infectious disease diagnostic testing
Recent Developments
(June 2026) 1-for-25 share consolidation approved and implemented to maintain Nasdaq listing compliance
(May 2026) Strong early data reported for Long COVID test with larger validation study planned
(April 2026) Full exercise of pre-funded warrants from $5 million private placement completed
(February 2026) ISO 13485:2016 and ISO 9001:2015 certifications achieved for quality management system
Open the full interactive Virax Biolabs Group Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.